# Aytu BioPharma Inc. (AYTU)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $20M  
**Price:** $2.21 (-1.56%)

> Aytu BioPharma Inc. is a specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), to improve patient quality of life. Its prescription portfolio features EXXUA (gepirone) extended-release tablets, the first and only FDA-approved selective serotonin 5HT1a receptor agonist for treating MDD in adults, alongside an ADHD portfolio with products like Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The company also markets a pediatric portfolio of legacy products such as Karbinal ER (carbinoxamine maleate), Poly-Vi-Flor, and Tri-Vi-Flor, addressing common pediatric conditions. Aytu BioPharma Inc. operates primarily through prescription pharmaceutical products sold via third parties and patient access programs like RxConnect pharmacies. Founded in 2002 and headquartered in Denver, Colorado, it plays a role in the pharmaceutical sector by commercializing novel therapeutics in CNS and related therapeutic areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $66M | $46M | -$8M | -$14M | — |
| 2024 | $65M | $49M | -$2M | -$16M | — |
| 2023 | $107M | $67M | -$17M | -$17M | — |
| 2022 | $97M | $52M | -$110M | -$109M | — |
| 2021 | $66M | $29M | -$59M | -$58M | — |
| 2020 | $28M | $19M | -$21M | -$14M | — |
| 2019 | $7M | $5M | -$17M | -$27M | — |
| 2018 | $4M | $2M | -$20M | -$10M | — |
| 2017 | $3M | $2M | -$20M | -$23M | — |
| 2016 | $3M | $2M | -$22M | -$28M | — |
| 2015 | $261,782 | $173,673 | -$8M | -$8M | — |
| 2014 | $58,929 | — | -$6M | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $124M | $105M | $19M | $31M | $11M |
| 2024 | $118M | $90M | $28M | $20M | $11M |
| 2023 | $136M | $97M | $39M | $23M | $15M |
| 2022 | $138M | $93M | $44M | $19M | $15M |
| 2021 | $266M | $128M | $138M | $50M | — |
| 2020 | $153M | $58M | $95M | $48M | — |
| 2019 | $35M | $28M | $7M | $11M | — |
| 2018 | $21M | $8M | $13M | $7M | — |
| 2017 | $15M | $11M | $4M | $802,328 | — |
| 2016 | $24M | $14M | $10M | $8M | — |
| 2015 | $18M | $3M | $16M | $7M | — |
| 2014 | $12M | $7M | $5M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$2M | $228,000 | -$2M |
| 2024 | -$1M | $329,000 | -$2M |
| 2023 | -$5M | — | — |
| 2022 | -$29M | — | — |
| 2021 | -$26M | — | — |
| 2020 | -$28M | — | -$28M |
| 2019 | -$14M | $59,848 | -$14M |
| 2018 | -$16M | $74,707 | -$16M |
| 2017 | -$14M | $111,608 | -$14M |
| 2013 | -$37,704 | — | — |
| 2012 | -$37,849 | — | — |
| 2011 | -$64,818 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/AYTU)